Otonomy vs Vertex Pharmaceuticals Incorporated
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Vertex Pharmaceuticals Incorporated is the larger company by market value: $134.3 B against $113 M for Otonomy, 1188 times as much (market caps of Jan 7, 2022 for Otonomy and Oct 29, 2026 for Vertex Pharmaceuticals Incorporated). Otonomy's value is the last on file, from Jan 7, 2022: no market-data feed is connected for its exchange yet.
- Vertex Pharmaceuticals Incorporated had more revenue: $12.0 B in the year to December 2025 against $0 M for Otonomy in the year to December 2020.
- Vertex Pharmaceuticals Incorporated made a net profit of $4.0 B, while Otonomy made a net loss of $45 M.
- Vertex Pharmaceuticals Incorporated keeps more of each dollar of sales: a net margin of 32.9% against -16555.6% for Otonomy.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Otonomy OTIC | Vertex Pharmaceuticals Incorporated VRTX · #171 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2008 | 1989 |
| Size | ||
| Market cap | $113 M* | $134.3 B |
| Revenue | $0 M | $12.0 B |
| Net income | $-45 M | $4.0 B▲ best |
| Employees | — | 6,400 |
| Valuation | ||
| P/E ratio | — | 33.8× |
| Price to sales | — | 10.4× |
| Price to book | — | 7.2× |
| Free cash flow yield | — | 2.4% |
| Profitability | ||
| Gross margin | — | 86.2% |
| Operating margin | — | 34.8% |
| Net margin | — | 32.9% |
| Return on equity | — | 22.5% |
| Return on invested capital | — | 26.2% |
| Growth | ||
| Revenue growth | — | 8.9% |
| Revenue growth, 3 years a year | — | 10.3% |
| Financial strength | ||
| Debt to equity | — | 0.0× |
| Net debt to EBITDA | — | -1.2× |
| Cash | ||
| Free cash flow margin | — | 26.6% |
| Shareholder returns | ||
| Shareholder yield | — | 1.5% |
| Altman Z-score zone | — | safe |
| Data as of | Market cap Jan 2022 | Market cap Oct 2026; ratios FY2025 |
▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither
Questions and answers#
Which is bigger, Otonomy or Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated is the larger company by market value: $134.3 B against $113 M for Otonomy, 1188 times as much (market caps of Jan 7, 2022 for Otonomy and Oct 29, 2026 for Vertex Pharmaceuticals Incorporated). Otonomy's value is the last on file, from Jan 7, 2022: no market-data feed is connected for its exchange yet.
Which makes more money, Otonomy or Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated had more revenue: $12.0 B in the year to December 2025 against $0 M for Otonomy in the year to December 2020. Vertex Pharmaceuticals Incorporated made a net profit of $4.0 B, while Otonomy made a net loss of $45 M.
Which is more profitable, Otonomy or Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated keeps more of each dollar of sales: a net margin of 32.9% against -16555.6% for Otonomy.
More about Otonomy
More about Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated: company page
- Who owns Vertex Pharmaceuticals Incorporated?
- Vertex Pharmaceuticals Incorporated market cap history
- Vertex Pharmaceuticals Incorporated revenue by year
- How many employees does Vertex Pharmaceuticals Incorporated have?
- Is Vertex Pharmaceuticals Incorporated cheap or expensive?
- Vertex Pharmaceuticals Incorporated against its peers: ranks and percentiles
Sources#
Every figure on this page comes from these, with the date shown next to it.